Supernus Announces Issuance of Third US Patent Protecting Oxtellar XR(R)

Supernus Announces Issuance of Third US Patent Protecting Oxtellar XR(R)

ROCKVILLE, Md., Jan. 7, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,
Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced the
issuance of a third patent (number 8,617,600) by the United States Patent and
Trademark Office (USPTO) covering Oxtellar XR®, its novel once-daily
extended-release oxcarbazepine product. The patent was issued by the USPTO on
December 31, 2013. It provides protection for the product with expiration that
is no earlier than 2027.

"We are committed to building our intellectual property protection for our
products to ensure longevity of our assets. We now have patent protection on
Oxtellar XR® through three issued U.S. patents and on Trokendi XR™ through two
issued U.S. patents," said Jack A. Khattar, President and CEO of Supernus.

Supernus has several additional patent applications for extended-release
topiramate and extended-release oxcarbazepine pending in other geographic
regions.

About Oxtellar XR®

Oxtellar XR is the only approved novel once-daily extended release formulation
of oxcarbazepine for the treatment of epilepsy. It is an antiepileptic drug
indicated for adjunctive therapy in the treatment of partial seizures in
adults and in children 6 to 17 years of age. The product is available in 150
mg, 300 mg and 600 mg extended-release tablets.

For full prescribing and safety information, click here.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of central
nervous system, or CNS, diseases. The Company has two marketed products for
epilepsy, Oxtellar XR™ (extended-release oxcarbazepine) and Trokendi XR™
(extended-release topiramate). The Company is also developing several product
candidates in psychiatry to address large market opportunities in ADHD,
including ADHD patients with impulsive aggression. These product candidates
include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

Forward Looking Statements

This press release contains forward-looking statements regarding the potential
of Oxtellar XR and Trokendi XR and intellectual property protection. Actual
results may differ materially from those in these forward-looking statements
as a result of various factors, including, but not limited to, risks regarding
the company's ability to commercialize the product successfully, whether
physicians will prescribe and patients will use the product, and competition
in the market. For a further description of these and other risks facing the
Company, please see the risk factors described in the Company's Annual Report
Form 10-K that was filed with the United States Securities and Exchange
Commission on March 15, 2013 and under the caption "Risk Factors" and the
updates to these risk factors in the Company's quarterly report form 10-Q that
was filed with the Commission on August 15, 2013. Forward-looking statements
speak only as of the date of this press release, and the company undertakes no
obligation to update or revise these statements, except as may be required by
law.

CONTACT: Jack A. Khattar, President and CEO
         Gregory S. Patrick, Vice President and CFO
         Supernus Pharmaceuticals, Inc.
         Tel: (301) 838-2591
 
Press spacebar to pause and continue. Press esc to stop.